Clearmind Medicine 和 SciSparc Ltd. 公布了基于氯胺酮的联合治疗的专利申请。 Clearmind Medicine and SciSparc Ltd. publish patent application for Ketamine-based combination treatments.

Clearmind Medicine and SciSparc Ltd.宣布根据《国际专利合作条约》公布一项基于氯胺酮的新型混合治疗专利申请。 Clearmind Medicine and SciSparc Ltd. announced the publication of a patent application for innovative Ketamine-based combination treatments under the international Patent Cooperation Treaty. 他们的合作重点是将SciSparc的PEA和Clearmind的MEAI结合起来,治疗成瘾,促进减肥,并解决心理健康疾病。 Their collaboration focuses on combining SciSparc's PEA and Clearmind's MEAI to treat addictions, promote weight loss, and address mental health disorders. 迄今为止,已经提出了13项与这种合作有关的专利申请。 To date, 13 patents related to this collaboration have been filed.

August 29, 2024

589 文章